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The renin-angiotensin system (RAS) plays pivotal roles in the regulation of cardiovascular
and renal functions to maintain the fluid and electrolyte homeostasis. Experimental studies
have demonstrated a locally expressed RAS in the carotid body, which is functional
significant in the effect of angiotensin peptides on the regulation of the activity of
peripheral chemoreceptors and the chemoreflex. The physiological and pathophysiological
implications of the RAS in the carotid body have been proposed upon recent studies
showing a significant upregulation of the RAS expression under hypoxic conditions
relevant to altitude acclimation and sleep apnea and also in animal model of heart
failure. Specifically, the increased expression of angiotensinogen, angiotensin-converting
enzyme and angiotensin AT1 receptors plays significant roles in the augmented carotid
chemoreceptor activity and inflammation of the carotid body. This review aims to
summarize these results with highlights on the pathophysiological function of the RAS
under hypoxic conditions. It is concluded that the maladaptive changes of the RAS
in the carotid body plays a pathogenic role in sleep apnea and heart failure, which
could potentially be a therapeutic target for the treatment of the pathophysiological
consequence of sleep apnea.
Keywords: angiotensin II, AT1 receptor, carotid body, intermittent hypoxia, OSA
INTRODUCTION
The renin-angiotensin system (RAS) plays important physiologi-
cal roles in the humoral regulation of blood pressure, electrolyte
and fluid homeostasis (Peach, 1977). The physiological effects
are mediated by bioactive angiotensin (Ang) peptides includ-
ing Ang II, Ang III, Ang IV, and Ang (1-7), produced by renin,
angiotensin-converting enzyme (ACE), ACE-2 and angiotensin-
processing peptidases, via the angiotensin AT1, AT2, AT4, and
Mas receptors (Figure 1). In addition to the endocrine func-
tion of RAS, growing amount of evidence demonstrates that
the intrinsic RAS functions in an autocrine-paracrine manner,
mediated by the RAS components expressed in numerous tissues
and organs. The local RAS has diverse effects on, for examples,
the regulation of vascular tone, generation of reactive oxygen
species (ROS), inflammation or fibrogenesis, which are regulated
by various physiological stimuli or pathophysiological conditions
(Campbell, 2003). As such, it has been proposed that the local
RAS might be a potential therapeutic target for the treatment of
disease.
Arterial chemoreceptors in the carotid body are important for
the rapid adjustment of respiratory and cardiovascular activi-
ties via the chemoreflex elicited by the sensory afferent activity
of the chemoreceptor responding to changes in chemical stimuli
in the arterial blood. The carotid body is a highly vascular-
ized organ with blood perfusion far exceeding the needs of its
local tissue metabolism. Thus, changes in arterial oxygen ten-
sion or pH, circulating humoral and locally produced signaling
substances acting as paracrines or autocrines can readily diffuse
to the chemosensory components of the carotid body. In addi-
tion to the response to hypoxia, hypercapnia and acidosis, the
carotid chemoreceptor responds to Ang II because AT receptors
are expressed in the chemosensitive glomus cell of the carotid
body (Allen, 1998; Fung et al., 2001). Moreover, the level of
RAS gene expression in the carotid body is regulated by hypoxia
(Leung et al., 2000; Fung et al., 2002). In this context, the aug-
mented activity of the carotid body has been proposed to play a
role in the pathophysiology of sleep apnea. Hence, the molecu-
lar and cellular mechanisms that mediate the effect of hypoxia on
the RAS in the carotid body and the pathophysiological role of
the RAS in disease conditions associated with hypoxemia are of
great interest. Research studies have been focused on: (a) mecha-
nisms underlying the carotid chemoreceptor response to Ang II;
(b) the expression of RAS components in the carotid body; (c)
the regulation of the RAS expression in the carotid body, and
(d) pathophysiological roles of the alteration of the RAS in the
carotid body in disease conditions associated with hypoxemia.
This review aims to summarize the literature on the functional
expression of RAS in the carotid body and its regulation by
hypoxia, highlighting the pathophysiological roles of the RAS in
the carotid body and its clinical implications.
EXPRESSION OF RAS COMPONENTS IN THE CAROTID BODY
The expression and localization of several key RAS components,
notably angiotensinogen, which is an indispensable component
for the existence of an intrinsic RAS, have been detected in the
rat carotid body (Lam and Leung, 2002). Hence, the mRNA and
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FIGURE 1 | Main components of the renin angiotensin system and the
enzymes mediating the proteolytic process in the carotid body. Arrows
denote the main direction of the physiological or pathophysiological cascade.
Note the renin-independent biosynthetic pathway and the enzymes involved
are shown in italic. The major physiological effect of Ang II is mediated by the
AT1 and AT2 receptors. In addition, the Ang II metabolites Ang IV and Ang
(1-7) exert biological effects via AT4 and Mas receptors, respectively. ACE,
angiotensin-converting enzyme.
protein of angiotensinogen are expressed in the chemosensitive
glomus cells. In addition, mRNA expression of ACE is present
despite an absence of the expression of renin in the rat carotid
body. These strongly support the localization of an intrinsic
angiotensin-generating system functioning via a locally renin-
independent biosynthetic pathway in the carotid body (Figure 1).
In this regard, the local angiotensin generation of Ang I and
Ang II could be mediated by renin in the circulating blood
or functional homologous enzymes of renin including tonin,
cathepsin G, and kallikrein (Figure 1). Also, angiotensin pep-
tides could be generated by renin-like enzymes expressed in the
vasculature (Campbell, 2003). However, the expression of these
alternative enzymes in the carotid body has not been investi-
gated. Nevertheness, Ang II locally produced in the carotid body
could elevate the local Ang II levels functioning as a paracrine-
autocrine signal via the activation of AT1 receptors expressed in
the glomus cells.
EXPRESSION AND FUNCTION OF ANGIOTENSIN RECEPTORS
IN THE CAROTID BODY
Peripheral infusion of Ang II stimulates respiration in anes-
thetized animals (Potter and McCloskey, 1979; Ohtake and
Jennings, 1993; Ohtake et al., 1993). The respiratory response to
Ang II is in part mediated by the carotid chemoreflex because
Ang II increases afferent activities of the carotid body (McQueen,
1981; Allen, 1998). The effect of Ang II may be mediated by the
sympathetic and parasympathetic efferent fibers innervating the
carotid body, which could increase the release of norepinephrine
and the afferent activity of the carotid body (McQueen, 1981;
Gonzalez et al., 1994). Nevertheless, evidence suggests that Ang
II exerts its effect on the chemosensory component of the carotid
body. Hence, Ang II at concentrations ranging from physiologi-
cal to pharmacological levels induces a brief inhibition followed
by an excitation of afferent carotid sinus nerve activity in the
rat superfused carotid body preparation (Allen, 1998; Leung
et al., 2000). The resting activity of the carotid sinus nerve is
dose-dependently increased by about two folds upon a thresh-
old concentration of 100 pM at the physiological level of Ang II
under normoxic conditions (Allen, 1998; Leung et al., 2000). Also,
both the inhibitory and excitatory effects of Ang II are blocked by
losartan, supporting the ligand binding is mediated by the AT1
receptors. In addition, in an autoradiographic study, AT receptor-
ligand bindings in the carotid body is not reduced by sympa-
thetic nor afferent denervation of the carotid body (Allen, 1998).
Indeed, Ang II elevates the level of intracellular calcium in the
chemosensitive glomus cells (Fung et al., 2001). The intracellular
calcium response to Ang II is blocked by losartan but not by an
antagonist for AT2 receptors PD-123319, suggesting an involve-
ment of AT1 receptors. Furthermore, AT1-immunostaining is
positively localized in the lobule of the rat carotid body, strongly
supporting the expression of AT1 receptors in the glomus cells
clustering in glomeruli (Fung et al., 2001). In fact, AT1 recep-
tors are co-localized with cells containing tyrosine hydroxylase,
which is a cellular marker of the biosynthesis of catecholamines
for the chemotransduction in the carotid body (Fung et al., 2002).
However, the AT1-immunoreactivity is not found in all lobules of
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the parenchyma, meaning that the expression of AT1 receptors
is not ubiquitous in the carotid body under physiological condi-
tions (Fung et al., 2001). This is in consistent with functional data
showing that the proportional amount of glomus cells respon-
sive to Ang II is about 40% (Fung et al., 2001). Nevertheless,
these findings are conclusive that AT1 receptors expressed in the
chemosensitive glomus cell mediate the carotid chemoreceptor
response to Ang II. It is known that Ang II binding of the AT1
receptor stimulates the phospholipase C pathway in the plasma
membrane and leads to the formation of 1,2-diacylglycerol and
inositol-1,4,5-triphosphate (IP3), which mobilizes the endoplas-
mic calcium to store and elevate intracellular calcium (Balla et al.,
1998). It is speculated that similar intracellular pathways could
mediate the effect of Ang II on the glomus cells and the details of
the intracellular signaling pathways need further study.
The mRNA transcript of two subtypes of AT1 receptors, AT1a
and AT1b, is expressed in the rat carotid body (Leung et al., 2000;
Fung et al., 2002). It has been shown that the AT1a receptor is the
main one accounting for the Ang II effect on the chemoreceptor,
whereas AT1b might have limited involvement, if any, in the early
stage of the maturation. In the postnatal rat, there is an increase
in the expression of AT1a subtype but a decrease in the AT1b sub-
type regulated by hypoxia (Fung et al., 2002). This suggests that
the AT1a receptor is the major subtype accounting for the Ang II
effect on the carotid body (Fung et al., 2002). In addition to AT1
receptors, mRNA transcripts of the AT2 receptor were found in
the carotid body (Leung et al., 2000; Fung et al., 2002). Activation
of the AT2 receptor has a wide spectrum of effects for instances
on vasodilation, apoptosis and anti-proliferation depending on
the cell type (Padia and Carey, 2013). Although the AT1 receptor
is the major one mediating the excitatory response of the carotid
chemoreceptor, it is possible that Ang II can also exert its effects
via the AT2 receptors in the carotid body.
It has been reported that AT4 and Mas receptors are expressed
in the carotid body (Fung et al., 2007; Schultz, 2011). Ang IV is an
Ang II metabolite containing the 3–8 fragment of the octapep-
tide, which exerts its physiological effect via the AT4 receptor.
It has been reported that activation of AT4 receptors by Ang IV
augments the release of acetylcholine in the hippocampus (Chai
et al., 2004). In the rat carotid body, positive immunoreactivity
against AT4 receptors was found in the chemosensitive glomus
cells containing the tyrosine hydroxylase (Fung et al., 2007). It is
speculated that AT4 receptors binding with Ang IV could enhance
the excitatory effect of Ang II on the carotid chemoreceptor medi-
ated by the AT1 receptor. Supporting this idea, the expression of
AT4 receptors in the carotid body is significantly increased under
chronically hypoxic condition. Also, Ang IV elevates the intra-
cellular calcium level of the chemosensitive glomus cells despite
at a high concentration (10µM) of Ang IV (Fung et al., 2007).
Thus, the AT4 receptor could be a signaling pathway of the RAS
in parallel and/or complementary to the AT1 receptor activa-
tion. The physiological or pathophysiological significance, if any,
of the AT4 receptor expressed in the carotid body has yet to be
fully elucidated in future studies. As for the Mas receptor, it is
a G-protein coupling receptor with high affinity binding with
Ang (1-7), a biologically active peptide converted from Ang I and
Ang II, respectively, by ACE2 and ACE. Recent study reported the
expression of Mas receptors in the rabbit carotid body and also its
decreased expression under a disease condition associated with
heart failure (Schultz, 2011). The signaling cascade of Mas recep-
tor activation has been known to induce vasodilation, which is
possibly a negative modulation of the functional effects of AT1
receptors. Thus, the Mas receptor may be functionally important
in the modulation of the RAS activity in the carotid body and
its alteration under disease condtions could be pathologically sig-
nificant as it may contribute to the imbalance of excitatory and
inhibitory modulation of the carotid chemoreceptor activity in
disease (Schultz, 2011).
FUNCTIONS OF LOCAL RAS COMPONENTS IN THE CAROTID
BODY
The circulating RAS is responsive to alterations in extracellu-
lar fluid volume, osmolarity, blood volume or sodium depletion,
resulting in an elevated level of Ang II in the plasma (Reid et al.,
1978; Matsusaka and Ichikawa, 1997). In addition to the vasocon-
strictive effect of Ang II and its stimulating effect on the aldos-
terone secretion by the adrenal cortex, Ang II stimulates carotid
chemoreceptors, which elicits the chemoreflex for the adjustment
in cardiopulmonary and autonomic activities. Specifically, acti-
vation of the chemoreflex pathway is known to elevate renal
sympathetic activities leading to the secretion of renin from the
juxtaglomerular cells in the kidney, which could then increase
sodium reabsorption and water intake (Honig, 1989; Marshall,
1994). Thus, the physiological significance of the effect of Ang
II on the carotid chemoreceptor is that the baseline activity of
the carotid chemoreceptor is regulated by Ang II in the circu-
lating blood and also produced by the local RAS, which could
elicit the chemoreflex in the absence of hypoxia, hypercapnia, or
acidosis. As such, the carotid chemoreceptor could serve as an
effector of Ang II for the regulation of blood pressure, electrolyte,
and fluid homestasis via the chemoreflex pathway. Moreover,
Ang II could potentiate the carotid chemoreceptor response to
hypoxia. The plasma Ang II level significantly increases under
hypoxic conditions (Zakheim et al., 1976). Also, the presence
of local RAS in the carotid body could elevate the level of Ang
II and also its metabolites in the local tissue, which could be
a major source of Ang II for a more prominent effect on the
modulation of the carotid chemoreceptor activity under hypoxic
or disease conditions. Hence in parallel to the function of Ang
II-sensitive neurons in the circumventricular organs of the brain
(Ganong, 2000; McKinley et al., 2003), the carotid chemoreceptor
can be an additional effector of Ang II, which confers and pro-
vides the peripheral signal integrating to the central output that
alters sympathetic and parasympathetic activities for the regula-
tion of cardiovascular and renal activities and also the electrolyte
and fluid homeostasis under physiological, hypoxic, and disease
conditions.
SUSTAINED HYPOXIA REGULATES RAS EXPRESSION:
IMPLICATIONS ON CHRONIC OBSTRUCTIVE PULMONARY
DISEASE
It has been shown that proportion of Ang II-responsive glomus
cells (ca. 80%) is increased by 2 folds in the carotid body of rats
exposed to 10% inspired oxygen for 4 weeks (sustained hypoxia)
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(Leung et al., 2000; Fung et al., 2001, 2002). Also, elevated intra-
cellular calcium levels induced by Ang II is three times higher
following sustained hypoxia than the normoxic group, which
is blocked by losartan (Leung et al., 2000; Fung et al., 2002).
Importantly, AT1 receptor-mediated excitation of carotid body
chemoreceptor activity is two times higher in rats exposed to sus-
tained hypoxia than in controls (Leung et al., 2000; Fung et al.,
2002). Thus, sustained hypoxia induces a significant increase in
the sensitivity of the chemoreceptor response to Ang II. In fact,
the mRNA expression of the AT1 and AT2 receptor is increased
in the carotid body of adult rats exposed to sustained hypoxia
(Leung et al., 2000). Also, there is an increased immunoreactivity
of AT1receptors in glomic clusters containing tyrosine hydroxy-
lase in the carotid body of rats with sustained hypoxia (Fung et al.,
2002). Interestingly, in postnatal exposure to sustained hypoxia,
the mRNA expression of AT1a receptors but not the AT1b sub-
type in the rat carotid body is upregulated, suggesting that the
expression of AT1 receptor subtypes is differentially regulated by
postnatal hypoxia (Fung et al., 2002). Thus, chronic hypoxemia
is a major factor that increases the expression of AT1a receptor
at the transcriptional and protein level, resulting in a functional
enchancement of the sensitivity of the carotid chemoreceptor to
Ang II.
In addition to the upregulation of the AT1 receptor, sustained
hypoxia induces increased expressions of several key components
of the RAS in the rat carotid body. The effect of sustained hypoxia
on the RAS component of the carotid body are: (i) it increases
the mRNA and protein level of angiotensinogen expressed in the
chemosensitive glomus cell, and (ii) elevated the mRNA expres-
sion and enzymatic activities of ACE (Lam and Leung, 2003;
Lam et al., 2004). The significance of these RAS alterations reg-
ulated by hypoxia is that it could increase the local biosynthesis
of Ang II and angiotensin peptides, which increases the carotid
chemoreceptor activity; via the chemoreflex, changes the respira-
tory and cardiovascular activities to match metabolic needs and
also adjustments of the autonomic and renal activities to regulate
the electrolyte and fluid homeostasis in hypoxia (Honig, 1989).
In addition, the increased expression of the AT1 receptor could
raise the sensitivity of the carotid body to the electrolyte and fluid
disturbance under hypoxic conditions. Indeed, the plasma con-
centration of Ang II rises in the first week of sustained hypoxia
but it returns to a normoxic level by 2 weeks (Zakheim et al.,
1976). The plasma renin activity has been reported to be unal-
tered or increased during hypoxia (Jain et al., 1990; Fletcher
et al., 1999; Ip et al., 2002). Thus, the increased expression and
activities of the RAS components could play a role in the aug-
mented activity of the carotid chemoreceptor and the chemoreflex
pathway by which increases and sustains the renal sympathetic
activity under hypoxic conditions. This could lead to activation
of the renin-angiotensin-aldosterone system, which is important
to increase the sodium and water retention. This might be a
part of the compensatory changes following the natriuretic and
diuretic effects of carotid chemoreceptor stimulation in acute
hypoxia (Honig, 1989). Consequently, the increased sensitivity of
the carotid body to Ang II could play a role in the augmentation
of cardiorespiratory and the renal sympathetic activities, which
is an important part of the response to hypoxia. Moreover, Ang
II levels are significantly elevated under pathological conditions
for instances hypotension or hemorrhage. Indeed hypotension
induces an increase in the discharge rate of carotid chemorecep-
tors which may be due to a decrease in the blood flow to the
carotid body (Lahiri et al., 1980). The elevated carotid chemore-
ceptor activity could also be mediated by the AT1 receptors and
the upregulated RAS components in the carotid body (Leung
et al., 2000; Fung et al., 2002).
Sustained hypoxia is closely relevant to the physiological accli-
mation to high altitude, and also to clinical conditions includ-
ing chronic obstructive pulmonary disease and congenital heart
defects (Forth and Montgomery, 2003; Prabhakar and Peng,
2004). The upregulation of RAS components in the carotid body
and the augmented sensitivity of the chemoreceptors to Ang II
could play multiple roles in the response of the carotid body to
sustained hypoxia. Specifically, the carotid body develops hyper-
trophy and hyperplasia and also increases vasculature with angio-
genesis (Fung and Tipoe, 2003). Ang II is known as a mitogenic
factor effecting on vascular cells, although the effect on the glomic
tissue is not clear at the moment. In addition, sustained hypoxia
modulates the ventilatory response to hypoxia (Bisgard, 2000;
Lahiri et al., 2000, 2002). The chemosensitivity of the carotid body
to hypoxia is modulated by the counterbalance of effects of exci-
tatory and inhibitory components on the carotid chemoreceptor
(Bisgard, 2000; Prabhakar, 2001). Thus, the excitatory effect of
Ang II on the glomus cell could augment the chemosensitivity
of the carotid chemoreceptor, which may counteract the blunt-
ing effect of sustained hypoxia on the ventilatory response to
hypoxia. Yet, the extent of the effect of Ang II and the detail of
the molecular and cellular mechanisms underlying the functional
modulation of the chemoreceptor excitability for the acclima-
tized changes in the carotid body during hypoxia require further
studies.
The RAS plays important roles in the pathogenesis of dis-
ease conditions including hypertension, cardiac hypertrophy and
heart failure. It has been shown that AT1 receptor antagonist
olmesartan significantly lowers the blood pressure and reduces
proteinuria and glomerular damage mediated by oxidative stress
in hypertensive diabetic animals (Izuhara et al., 2005). It has
also been reported that ACE and Ang II play roles in the
hypoxia-induced pulmonary hypertension and vascular remod-
eling (Morrell et al., 1995, 1999). The pathological development
of hypoxic cor pulmonale is significantly decreased by olmesar-
tan in rats exposed to sustained hypoxia (Nakamoto et al., 2005).
However, in a double-blind study, losartan did not significantly
attenuate pulmonary hypertension in a cohort of 40 patients
with chronic obstructive pulmonary disease (Morrell et al., 2005).
Also, irbesartan, an AT receptor blocker, did not significantly
alter the strength of respiratory muscles or spirometric param-
eters in a randomized trial with about 60 patients with chronic
obstructive pulmonary disease, although it significantly decreased
the hematocrit. This raises the possibility that blockade of AT
receptors may have beneficial effects in the patients with chronic
obstructive pulmonary disease (Andreas et al., 2006). A more
recent study reported that ACE inhibitor enalapril or AT recep-
tor blocker losartan reduced the mortality of 2249 patients with
severe COPD (Ekström et al., 2013). The effect of RAS blockade
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in disease associated with hypoxia needs more clinical trial studies
in future.
INTERMITTENT HYPOXIA REGULATES RAS EXPRESSION:
IMPLICATIONS ON SLEEP-DISORDERED BREATHING
Chronic exposure to episodic hypoxia (intermittent hypoxia)
associated with recurrent apneas closely related to pathophysio-
logical conditions including sleep-disordered breathing, obstruc-
tive sleep apnea and hypertension (Lesske et al., 1997; Fletcher,
2001). Evidence suggests that the carotid body plays a crucial role
in the pathophysiology of sleep apnea and it pathophysiological
consequences induced by intermittent hypoxia (Prabhakar et al.,
2001, 2005; Peng et al., 2003; Iturriaga et al., 2005). Thus, there is
an augmented carotid chemoreceptor activity and its chemosen-
sitivity in animals exposed to intermittent hypoxia (Peng and
Prabhakar, 2004; Peng et al., 2004; Rey et al., 2004). Also, inter-
mittent hypoxia induces increases in the blood pressure (Fletcher
et al., 1992a,b), activities of sympathetic nerve (Greenberg et al.,
1999; Fletcher, 2003), plasm levels of catecholamines (Bao et al.,
1997), long-term facilitation (LTF) of the respiratory motor activ-
ity and the ventilatory response to hypoxia (McGuire et al., 2004;
Rey et al., 2004; Katayama et al., 2005). Moreover, denervation of
the carotid afferent activity dramatically attenuates the elevated
blood pressure in responding to intermittent hypoxia, indicat-
ing that the carotid chemoreceptor activity plays an important
role in the pathogenic cascades induced by intermittent hypoxia
(Fletcher et al., 1992a). Furthermore, intermittent hypoxia resem-
bles ischemia-reperfusion of tissues and organs, leading to exces-
sive production of ROS, which could underpin the long-term
effects of intermittent hypoxia on the carotid body. This is sup-
ported by the observation that ROS scavengers attenuate the
hypoxic sensitivity and the magnitude of LTF induced by inter-
mittent hypoxia (Prabhakar and Kumar, 2004). Thus, ROS play
a crucial role in the altered carotid body function in intermittent
hypoxia.
As aforementioned, Ang II stimulates ventilation and the
plasma Ang II level increases under hypoxic conditions (Zakheim
et al., 1976; Ohtake et al., 1993). Activation of AT1 recep-
tors in the carotid body increases the afferent activity and the
hypoxic sensory response of the chemoreflex and sympathetic
output (Leung et al., 2000). In experimental animals, losartan
significantly reduces the elevated arterial pressure induced by
intermittent hypoxia, suggesting that the RAS is involved in the
pathogenic cascade (Fletcher et al., 1999). Indeed, there are sig-
nificantly increased levels of serum Ang II and VEGF in patients
with obstructive sleep apnea (Barcelo et al., 2001; Moller et al.,
2003). Blocker of AT1 receptors olmesartan significantly decreases
the VEGF expression induced by Ang II in the peripheral blood
mononuclear cell (Takahashi et al., 2005). Thus, activation of the
AT1 receptor plays a role in the pathogenic event of obstruc-
tive sleep apnea. Recent studies have examined the hypothesis
that the RAS in the carotid body plays a role in the augmented
carotid chemoreceptor activity induced by intermittent hypoxia,
which may be mechanistically leading to breathing instability in
the pathophysiology of sleep apnea.
Recent studies reported that intermittent hypoxia induces a
functional upregulation of the RAS expression in the rat carotid
body (Lam et al., 2014). The increasedmRNA and protein expres-
sion of AT1 receptors causes an enhancement of the sensitivity to
Ang II in the carotid chemosensitive cells, which could lead to
an increase in the CB excitability and renal sympathetic activity
(Marcus et al., 2010; Lam et al., 2014). In effect, the activation of
RAS in the carotid body during intermittent hypoxia has patho-
physiological and clinical significance because the chemoreflex
plays an important role in the sustained increases in the sympa-
thetic outflow and the systemic arterial pressure (Fletcher, 2001).
Indeed, it has been shown that the systemic hypertension induced
by intermittent hypoxia is blocked by the denervation of the
carotid body, ablation of the sympathetic nerve, renal sympathec-
tomy, adrenal medullectomy, and also by AT receptor antagonist
(Fletcher et al., 1999; Fletcher, 2001). These data support the
hypothesis that the RAS expression in the carotid body plays a
role in the pathogenic cascade induced by intermittent hypoxia,
which increases the cardiovascular morbidity in OSA patients.
Ang II stimulates the [Ca2+]i elevation in the chemosensi-
tive glomus cells and the Ang II response is enhanced in the
hypoxic group via the upregulation of AT1 receptor expression
(Lam et al., 2014). The [Ca2+]i response to AT was inhibited by
AT1 antagonist losartan but not by an AT2 antagonist, confirming
that AT binding to the AT1 receptor stimulates the intracellular
signaling pathway and elevates [Ca2+]i in the glomus cells. In
effect, Ang II evokes sensory long-term potentiation of the carotid
body, which was blocked by losartan (Peng et al., 2011). Also,
losartan reduced the elevated sympathetic responses to hypoxia
and cyanide (Marcus et al., 2010). These results suggest that the
upregulation of the AT1 receptor expression plays a role in the
augmented CB excitability during intermittent hypoxia, high-
lighting the mechanistic significance of the RAS in mediating
the IH-induced pathophysiological development of sympathetic
overactivity and hypertension.
In addition to AT1 receptors, the gene transcripts of AT2
receptor have shown to be increased in the carotid body in inter-
mittent hypoxia. The increased expression of the AT2 receptors
might be related to the lack of increase in the volume of the
carotid body in the rat (Lam et al., 2008). Indeed, AT2 recep-
tors have been implicated in the stimulation of apoptosis and
the activation of AT2 receptor results in growth inhibition and
promotion of apoptosis associated with the inhibition of MAP
kinases, such as extracellular regulated kinases, probably by the
activation of phospho-tyrosine phosphatase (Schmitz and Berk,
1997; de Gasparo and Siragy, 1999). The activated local RAS via
AT2 receptors in the carotid body might inhibit the cell growth
and promote apoptotic cell death, resulting in an insignificant
change in the volume of the carotid body in intermittent hypoxia.
However, further investigations are needed for addressing the role
of AT2 receptors in the carotid body.
Moreover, the expression of angiotensinogen in the carotid
body is significantly elevated by intermittent hypoxia (Lam et al.,
2014). The mRNA and protein expression of angiotensinogen
was specifically localized to the glomus cells of the carotid body,
suggesting a transcriptional upregulation and/or mRNA stabiliza-
tion of the angiotensinogen expression induced by intermittent
hypoxia. Also, the mRNA level of ACE was significantly increased
in the rat carotid body (Lam et al., 2014). Thus, evidence supports
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that intermittent hypoxia induces an upregulation of the local
RAS components in the rat carotid body. Since angiotensinogen
is the sole precursor of Ang II, elevated levels of the expression of
angiotensinogen could lead to an increase in the local production
of Ang II in the carotid body in intermittent hypoxia. Moreover,
the increased expression of ACE in the carotid body could
enhance the kinetics of enzymatic convertion of Ang I to Ang
II in the carotid body. Also, increased ACE activities and plasma
Ang II levels have been reported in OSA patients (Barcelo et al.,
2001;Moller et al., 2003). In effect, the elevated level of circulating
and locally produced Ang II, together with an increased expres-
sion of the AT receptors could enhance the effect of Ang II on
the chemosensory component of the carotid body. Thus, evidence
supports the upregulated AT receptors with increased expression
of RAS components in the carotid body play a pathogenic role
in the augmented excitability of the carotid chemoreceptor under
intermittent hypoxia associated with sleep apnea.
Oxidative stress with an increased generation of ROS plays an
essential role in IH-induced alterations in the carotid body func-
tion (Prabhakar et al., 2001). It has been shown that ROS mod-
ulate the mobilization of [Ca2+]i store mediated by IP3signaling
pathway, leading to an increase in hypoxia-induced neurotrans-
mitter release in IH (Prabhakar and Kumar, 2004). Studies have
also shown that oxidative stress is involved in the augmented
carotid chemoreceptor activity (Pawar et al., 2009; Peng et al.,
2009; Del Rio et al., 2010, 2011b). Emerging data suggest that
Ang II is a mediator of oxidative stress, in which ROS induced
by Ang II are an important signaling intermediates in several
signal transduction pathways involved in the pathophysiology
(Paravicini and Touyz, 2006) and inflammation (Duprez, 2006).
In this regard, vascular inflammation induced by Ang II is mainly
mediated by AT1 receptors associated with an increased pro-
duction of ROS via the NADPH oxidase in the vascular wall
(Griendling et al., 1994; Rajagopalan et al., 1996; Dandona et al.,
2003), which is closely related to the local RAS function (Shimizu
et al., 1998). In the carotid body, AT receptors are also expressed in
the vascular cells in addition to the glomus cells, although its role
is unclear. Nevertheless, it has been shown that losartan treatment
could normalize IH-induced superoxide production and expres-
sion of AT1 receptors (Marcus et al., 2010). Also, ROS production
induced by Ang II mediates sensory long-term potentiation in the
carotid body via activation of gp91phox (Peng et al., 2011), and
the gp91phox is expressed in glomus cells of the CB (Youngson
et al., 1997). Thus, the IH–induced RAS upregulation in the
carotid body may contribute to the AT-induced ROS produc-
tion. Furthermore, losartan treatment of the rat in intermittent
hypoxia attenuates the levels of oxidative stress and macrophage
infiltration, supporting a pathogenic role of AT1 receptors in the
local inflammation of the carotid body (Lam et al., 2014). In this
context, intermittent hypoxia induces increased expressions of
proinflammatory cytokines and mediators as well as infiltration
of immunogic cells to the carotid body under hypoxic cond-
tions (Lam et al., 2008, 2012; Liu et al., 2009; Del Rio et al.,
2011a, 2012). The inflammatory response of the carotid body
to intermittent hypoxia has also been proposed to play a role in
the augmented activity of the carotid chemoreceptor (Lam et al.,
2008, 2012; Liu et al., 2009). These findings strongly suggest a
paracrine-autocrine mechanism mediating altered functions of
the carotid body, including the augmented chemosensitivity and
the local inflammation of the carotid body. Thus, intermittent
hypoxia could activate an intrinsic angiotensin-generating sys-
tem, which increases local biosynthesis of Ang II via increased
expressions of RAS components in the carotid body. The upreg-
ulation of angiotensinogen, AT receptors and ACE expression
could play a pathogenic role in the augmented activity of carotid
chemosensitive cells and the inflammation of the carotid body in
intermittent hypoxia, which is relevant to the early pathogenesis
in sleep-disordered breathing.
The RAS has been proposed to play a role in the cardiovascu-
lar consequences of sleep apnea, including systemic hypertension.
In addition to the continuous positive airway pressure therapy,
targeting the RAS has been proposed as a pharmacological man-
agement of the patients with sleep apnea. In fact, inhibitors of
ACE have been shown to attenuate the arterial pressures and
decrease the apnea and hypoapnea index in patients with obstruc-
tive sleep apnea (Peter et al., 1989; Mayer et al., 1990; Grote
et al., 1995). Also, the AT receptor blockers have been shown to
attenuate the elevated pressure and oxidative stress induced by
intermittent hypoxia in subjects (Foster et al., 2010; Pialoux et al.,
2011) or in the patient with obstructive sleep apnea (Heitmann
et al., 2010; Dohi et al., 2011). The beneficial effect of the RAS
blockade might be explained by diminished sympathetic and
adrenergic activities (Fletcher, 2000, 2003). Nevertheless, these
human studies were performed in a small number of patients and
the long term treatment with RAS blockers has not been evaluated
in clinical trials (Parati et al., 2013). Future clinical studies are
required to support the antihypertensive benefit of blockade of
RAS for the management of patients with obstructive sleep apnea
and hypertension.
AN INVOLVEMENT OF THE RAS IN HEART FAILURE
Experimental studies have shown that Ang II enhances the
hypoxic chemosensitivity of the carotid body in a rabbit model
of chronic heart failure (CHF). Hence, Ang II augments hypoxia-
induced renal sympathetic nerve activity (RSNA) and there
are significant increases in the expression of AT1 receptors in
the carotid body of CHF rabbits (Li et al., 2006). Also, L-
158809, an AT1 receptor antagonist, attenuates hypoxia-induced
responses of the RSNA in CHF rabbits. In addition, L-158809
decreases the chemoreceptor responses to hypoxia in CHF rab-
bits, suggesting that increases in Ang II and the expression of
AT1 receptor in the carotid body play a role in the augmented
carotid chemoreceptor activity and chemoreflex-mediated sym-
pathetic overactivity in CHF (Li et al., 2006). Furthermore,
Ang II at a concentration of 0.1 nM increases the sensitivity
of potassium (Kv) currents and resting membrane potential to
hypoxia and L-158809 reduces the sensitivity of Kv currents and
resting membrane potential to hypoxia in CHF glomus cells.
These results suggest that Ang II-AT1 receptor signaling pathway
increases the sensitivity of Kv channels to hypoxia in the glo-
mus cells of the CHF rabbit (Li and Schultz, 2006). Moreover,
the effect of Ang II on the augmented chemoreceptor activity
is medated by a NADPH oxidase-superoxide signaling pathway
(Li et al., 2007).
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Sleep-disordered breathing with central or obstructive sleep
apnea is frequently observed in patients with heart failure. Sleep-
disordered breathing has been known to have a negative impact
on the CHF patient and so clinical treatment of sleep-disordered
breathing could improve cardiac performance and long-term out-
comes in these patients. Also, cardiac dysfunction may play a
role in the pathophysiology of sleep apnea, although the inter-
relationship between heart failure and sleep apnea remains to
be established (Caples et al., 2005). In this context, an increase
in sympathetic activities is a hallmark of the CHF state, which
could be mediated by a decrease in the sensory feedback from
cardiopulmonary activities and arterial baroreceptors. As men-
tioned above, the sustained increase in RSNA could involve Ang
II and the RAS in the carotid body of CHF rabbits (Schultz, 2011;
Patel and Schultz, 2013). Indeed, recent studies show that cryoab-
lation of the carotid body normalizes the RSNA and breathing
stability and improves survival in CHF animals (Del Rio et al.,
2013; Marcus et al., 2014). Hence, the RAS components could be
therapeutic targets for the treatment of CHF patients.
CONCLUSIONS
Findings of expression and functional studies suggest that the
AT1 receptor regulates the excitability of the carotid chemore-
ceptor. Hence, Ang II elevates the level of intracellular cal-
cium in the chemosensitive glomus cells and the activity of
carotid chemoreceptors. As a result, activation of the chemore-
flex could be a peripheral control important for the physiological
response to hypoxia and the maintenance of electrolyte and
fluid homeostasis. In addition, the expression of AT receptors
in the carotid body is regulated by hypoxia. In effect, sustained
hypoxia induces an upregulation of AT1 receptor expression,
which increases the sensitivity of the chemoreceptor response
to Ang II. This regulation may be important in the modulation
of the carotid body functions responsible for the hypoxic ven-
tilatory response, for enhancing the cardiorespiratory response
and adjusting electrolyte and water homeostasis during sustained
hypoxia. Furthermore, RAS components are locally expressed in
the carotid body and the increased RAS expressions are closely
relevant to the pathogenesis of disease including sleep-disordered
breathing and heart failure. Specifically, the upregulation of the
expression of angiotensinogen, ACE and AT1 receptors could play
a significant role in the augmented carotid chemoreceptor activ-
ity, via the increased activity of chemoreflex, contributing to the
pathophysiology of sleep apnea and the sympatho-excitation that
is central to the endothelial dysfunction and heart failure during
the course of pathogenesis. Future studies in this direction war-
rant a better understanding of the pathogenic role of RAS in the
carotid body in the disease associated with hypoxemia.
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